Search Results for "Drug Interactions"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Drug Interactions. Results 61 to 70 of 281 total matches.
In Brief: A New Indication for Dabrafenib (Tafinlar) and Trametinib (Mekinist) Combination Therapy (online only)
The Medical Letter on Drugs and Therapeutics • Feb 06, 2023 (Issue 1669)
, dry skin, dermatitis
acneiform, abdominal pain, and paronychia also
occurred.
DRUG INTERACTIONS ...
The oral kinase inhibitors dabrafenib (Tafinlar – GSK)
and trametinib (Mekinist – Novartis) have received
accelerated approval by the FDA for use together
for a fifth indication: treatment of unresectable or
metastatic solid tumors with a BRAF V600E mutation
in patients ≥6 years old who have progressed
following prior treatment and have no satisfactory
alternative treatment options. The combination is not
approved for treatment of colorectal cancer because
of known intrinsic resistance to BRAF inhibition and
dabrafenib is not approved for use in patients with
wild-type BRAF...
Med Lett Drugs Ther. 2023 Feb 6;65(1669):e26-7 doi:10.58347/tml.2023.1669f | Show Introduction Hide Introduction
Belzutifan (Welireg) for Advanced Renal Cell Carcinoma (online only)
The Medical Letter on Drugs and Therapeutics • Apr 29, 2024 (Issue 1701)
creatinine, and potassium levels
have been reported.
▶ Drug Interactions: Concurrent use of UGT2B17 ...
Belzutifan (Welireg – Merck), a first-in-class hypoxia-inducible
factor inhibitor, has been approved by the
FDA for treatment of advanced renal cell carcinoma
(RCC) in adults who received prior treatment with a
programmed death receptor-1 (PD-1) or programmed
death-ligand 1 (PD-L1) inhibitor and a vascular
endothelial growth factor tyrosine kinase inhibitor
(VEGF-TKI). Belzutifan was previously approved for
use in patients with von Hippel-Lindau disease.
Med Lett Drugs Ther. 2024 Apr 29;66(1701):e75-6 doi:10.58347/tml.2024.1701g | Show Introduction Hide Introduction
Mavacamten (Camzyos) for Obstructive Hypertrophic Cardiomyopathy
The Medical Letter on Drugs and Therapeutics • Jun 13, 2022 (Issue 1652)
cause heart failure, interacts with many other drugs,
and is very expensive. Long-term data are needed ...
The FDA has approved mavacamten (Camzyos –
MyoKardia/BMS), a modulator of cardiac myosin, to
improve functional capacity and symptoms in adults
with New York Heart Association (NYHA) class II or
III obstructive hypertrophic cardiomyopathy (HCM)
who have a baseline left ventricular ejection fraction
(LVEF) ≥55%. Mavacamten is the first drug in its class
to become available in the US.
Comparison Table: Triptans for Migraine (online only)
The Medical Letter on Drugs and Therapeutics • Jun 12, 2023 (Issue 1678)
for
Drug Interactions
With a strong CYP3A4 inhibitor6:
6.25 mg starting dose
(max 12.5 mg/day); avoid ...
View the Comparison Table: Triptans for Migraine
Med Lett Drugs Ther. 2023 Jun 12;65(1678):e97-9 doi:10.58347/tml.2023.1678b | Show Introduction Hide Introduction
Lodoco: Low-Dose Colchicine for Cardiovascular Event Prevention
The Medical Letter on Drugs and Therapeutics • Oct 02, 2023 (Issue 1686)
outcomes. Colchicine is excreted in human
breast milk in low concentrations.
DRUG INTERACTIONS ...
Colchicine (Colcrys, and others), which has been
available in the US for decades for prophylaxis
and treatment of gout flares and other indications
in oral formulations that contain 0.6 mg of the
drug, has now been approved in 0.5-mg tablets as
Lodoco (Agepha) to reduce the risk of myocardial
infarction (MI), stroke, coronary revascularization,
and cardiovascular death in adults with established
atherosclerotic disease or multiple risk factors for
cardiovascular disease.
Med Lett Drugs Ther. 2023 Oct 2;65(1686):156-7 doi:10.58347/tml.2023.1686b | Show Introduction Hide Introduction
Opill — An OTC Oral Contraceptive
The Medical Letter on Drugs and Therapeutics • Sep 18, 2023 (Issue 1685)
in the risk of
breast cancer.8,9
DRUG INTERACTIONS — Drugs that induce hepatic
enzyme activity ...
The FDA has approved Opill (Perrigo), a progestin-only
oral contraceptive that contains norgestrel, for
sale over the counter (OTC). Opill is the first oral
contraceptive to be approved in the US for sale without
a prescription. Approval of OTC Opill is intended
to increase access to effective contraception and
reduce the rate of unintended pregnancies.
Med Lett Drugs Ther. 2023 Sep 18;65(1685):151-2 doi:10.58347/tml.2023.1685c | Show Introduction Hide Introduction
Sulbactam/Durlobactam (Xacduro) for Acinetobacter Pneumonia
The Medical Letter on Drugs and Therapeutics • Nov 27, 2023 (Issue 1690)
, and liver enzyme elevations were most common.
Drug Interactions: Use with organic anion transporter 1 ...
The FDA has approved Xacduro (Innoviva), a
combination of the beta-lactam antibacterial
sulbactam and the beta-lactamase inhibitor
durlobactam, for IV treatment of adults with hospital-acquired
or ventilator-associated bacterial pneumonia
caused by susceptible isolates of Acinetobacter
baumannii-calcoaceticus complex (ABC).
Med Lett Drugs Ther. 2023 Nov 27;65(1690):189-90 doi:10.58347/tml.2023.1690c | Show Introduction Hide Introduction
Comparison Table: Some Oral/Transdermal Opioid Analgesics (online only)
The Medical Letter on Drugs and Therapeutics • Dec 12, 2022 (Issue 1665)
infants whose mothers were taking
codeine
Drug Interactions
Concurrent use of other CNS depressants ...
View the Comparison Table: Some Oral/Transdermal Opioid Analgesics
Vibegron (Gemtesa) for Overactive Bladder
The Medical Letter on Drugs and Therapeutics • May 03, 2021 (Issue 1623)
has
been detected in the milk of lactating rats administered
radiolabeled vibegron.
DRUG INTERACTIONS — Taking ...
The FDA has approved the selective beta-3 adrenergic
agonist vibegron (Gemtesa – Urovant Sciences)
for treatment of overactive bladder in adults with
symptoms of urge urinary incontinence, urgency, and
urinary frequency. It is the second beta-3 agonist to
be approved in the US; mirabegron (Myrbetriq) was
the first.
Fruquintinib (Fruzaqla) for Metastatic Colorectal Cancer (online only)
The Medical Letter on Drugs and Therapeutics • Feb 19, 2024 (Issue 1696)
2 weeks before or after major surgery.
DRUG INTERACTIONS — Fruquintinib is a CYP3A
substrate ...
Fruquintinib (Fruzaqla – Takeda), an oral kinase
inhibitor, has been approved by the FDA for treatment
of adults with metastatic colorectal cancer (mCRC)
who received prior fluoropyrimidine-, oxaliplatin-, and
irinotecan-based chemotherapy, anti-VEGF therapy,
and, in patients with RAS wild-type mutations, anti-EGFR therapy. The drug can be used in patients with
mCRC regardless of biomarker status. Fruquintinib
is the first drug to become available in the US for
treatment of mCRC that targets 3 VEGF receptor
kinases.
Med Lett Drugs Ther. 2024 Feb 19;66(1696):e34-5 doi:10.58347/tml.2024.1696f | Show Introduction Hide Introduction